SAMSUNG BIOLOGICS CO.,LTD.
Financials
Valuation Metrics
SAMSUNG BIOLOGICS CO.,LTD.'s Market Cap is ₩64.6T. At end of 2025 it was ₩78.5T. Ranked #7 of 2,421 in KR market (top 0.3%), #7 of 781 on KOSPI (top 0.9%), #1 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 0.4%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 64.58T KRW | KR#7/2,421 Sec#1/231 |
| Revenue | 4.55T KRW | KR#141/2,421 Sec#2/231 |
| Net Income | 1.98T KRW | KR#27/2,421 Sec#1/231 |
| Total Assets | 12.65T KRW | KR#100/2,421 Sec#2/231 |
| Net Assets | 8.36T KRW | KR#68/2,421 Sec#2/231 |
| Employees | 5,011 | KR#59/2,421 Sec#1/231 |
| Value | ||
| P/E | 32.54x | KR#1,329/2,421 Sec#83/231 |
| P/B | 7.72x | KR#2,328/2,421 Sec#206/231 |
| PEG | 0.60x | KR#711/2,421 Sec#46/231 |
| P/S | 14.20x | KR#2,309/2,421 Sec#171/231 |
| EV/EBITDA | 28.85x | KR#1,182/2,421 Sec#73/231 |
| FCF Yield | 1.33% | KR#1,109/2,421 Sec#78/231 |
| Profitability | ||
| ROE | 23.73% | KR#116/2,421 Sec#10/231 |
| ROA | 15.68% | KR#106/2,421 Sec#9/231 |
| Op. Margin | 50.02% | KR#12/2,421 Sec#2/231 |
| Revenue Growth | -9.64% | KR#1,917/2,421 Sec#178/231 |
| Earnings Growth | 54.31% | KR#533/2,421 Sec#36/231 |
| Financial Health | ||
| Debt Ratio | 51.31% | KR#978/2,421 Sec#114/231 |
| Total Debt | 1.33T KRW | KR#169/2,421 Sec#4/231 |
| FCF | 856.07B KRW | KR#40/2,421 Sec#1/231 |
| Cash | 288.58B KRW | KR#206/2,421 Sec#4/231 |
| Current Ratio | 1.80x | KR#980/2,421 Sec#108/231 |
| Net Debt/EBITDA | 0.46x | KR#664/2,421 Sec#40/231 |
| Performance | ||
| 1Y Return | -7.89% | KR#918/2,421 Sec#56/231 |
| 1M Return | -9.65% | KR#2,083/2,421 Sec#174/231 |
| From 52W High | -29.79% | KR#520/2,421 Sec#32/231 |
| 1Y MDD | -36.74% | KR#458/2,421 Sec#34/231 |
| Trading | ||
| Volume | 22,978 shares | KR#1,515/2,421 Sec#148/231 |
| Trading Value | 32.07B KRW | KR#118/2,421 Sec#7/231 |
| Foreign Own. | 13.14% | KR#369/2,421 Sec#25/231 |
| Per Share | ||
| EPS | 42,866 KRW | KR#20/2,421 Sec#1/231 |
| BPS | 180,638 KRW | KR#78/2,421 Sec#3/231 |
Company Info
Established in 2011, this company is a biopharmaceutical CDMO specialist that incorporated development and commercialization divisions by acquiring 100% of Samsung Bioepis shares in 2022. It operates production facilities in Songdo, Incheon, offering contract manufacturing and cell line/process development services, and currently sells 10 types of biosimilars globally. The company is expanding from antibody drug-focused CDMO to next-generation biopharmaceuticals, aiming to complete an End-to-End service system with the launch of an organoid business in 2025. Samsung Biologics is headquartered in Yeonsu-gu, Incheon.